Methoxsalen
Oxsoralen-ultra, Uvadex (methoxsalen) is a small molecule pharmaceutical. Methoxsalen was first approved as 8-mop on 1982-01-01. It is used to treat mycosis fungoides, psoriasis, and vitiligo in the USA. It is known to target cytochrome P450 2A6.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Oxsoralen-ultra, Uvadex (generic drugs available since 2014-06-05, discontinued: 8-mop, Oxsoralen)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| uvadex | New Drug Application | 2021-03-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycosis fungoides | — | D009182 | C84.0 |
| psoriasis | EFO_0000676 | D011565 | L40 |
| vitiligo | EFO_0004208 | D014820 | L80 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Low back pain | D017116 | HP_0003419 | M54.5 | — | — | — | 2 | — | 2 |
| Wounds and injuries | D014947 | T14.8 | — | — | — | 1 | — | 1 | |
| Rib fractures | D012253 | — | — | — | 1 | — | 1 | ||
| Inguinal hernia | D006552 | HP_0000023 | K40 | — | — | — | 1 | — | 1 |
| Ventral hernia | D006555 | EFO_1001866 | K43 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | 3 | 1 | — | — | 3 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | 1 | — | — | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
| Postoperative pain | D010149 | G89.18 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Assisted reproductive techniques | D027724 | — | — | — | — | 1 | 1 | ||
| Infertility | D007246 | EFO_0000545 | — | — | — | — | 1 | 1 | |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Nephrolithiasis | D053040 | N20.0 | — | — | — | — | 1 | 1 | |
| Kidney calculi | D007669 | EFO_0004253 | N20.0 | — | — | — | — | 1 | 1 |
| Urolithiasis | D052878 | N20-N23 | — | — | — | — | 1 | 1 | |
| Ureteral calculi | D014514 | — | — | — | — | 1 | 1 | ||
| Ureteral diseases | D014515 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METHOXSALEN |
| INN | — |
| Description | Methoxsalen is a member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis. It has a role as a dermatologic drug, an antineoplastic agent, a photosensitizing agent, a cross-linking reagent and a plant metabolite. It is a member of psoralens and an aromatic ether. It is functionally related to a psoralen. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1c2occc2cc2ccc(=O)oc12 |
Target
Agency Approved
No data
Alternate
CYP2A6
CYP2A6
Organism
Homo sapiens
Gene name
CYP2A6
Gene synonyms
CYP2A3
NCBI Gene ID
Protein name
cytochrome P450 2A6
Protein synonyms
1,4-cineole 2-exo-monooxygenase, Coumarin 7-hydroxylase, CYPIIA6, Cytochrome P450 IIA3, Cytochrome P450(I), cytochrome P450, family 2, subfamily A, polypeptide 6, cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6, flavoprotein-linked monooxygenase, xenobiotic monooxygenase
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 927 documents
View more details
Safety
Black-box Warning
Black-box warning for: Uvadex
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,924 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more